UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Journal of infectious diseases, ISSN 0022-1899, 11/2014, Volume 210, Issue 9, pp. 1357 - 1366
Biofilms | Antibiotics | Escherichia coli | Bacteria | Aminoglycosides | Pseudomonas aeruginosa | Infections | Basic amino acids | Staphylococcus aureus | aminoglycoside | persister | catheter-related infections | biofilm | proton motive force | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Escherichia coli Infections - prevention & control | Central Venous Catheters - microbiology | Escherichia coli - drug effects | Gentamicins - administration & dosage | Catheter-Related Infections - prevention & control | Pseudomonas Infections - prevention & control | Arginine - administration & dosage | Gentamicins - pharmacology | Drug Therapy, Combination | Biofilms - drug effects | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Pseudomonas Infections - drug therapy | Rats | Central Venous Catheters - adverse effects | Pseudomonas aeruginosa - drug effects | Catheter-Related Infections - drug therapy | Drug Synergism | Animals | Arginine - pharmacology | Staphylococcal Infections - prevention & control | Anti-Bacterial Agents - pharmacology | In Vitro Techniques | Staphylococcus aureus - drug effects | Hydrogen-Ion Concentration | Health aspects | Research | Index Medicus | Abridged Index Medicus | Biofilms/drug effects | Gentamicins/administration & dosage | Anti-Bacterial Agents/pharmacology | Staphylococcal Infections/drug therapy | Arginine/administration & dosage | Life Sciences | Escherichia coli Infections/drug therapy | Staphylococcus aureus/drug effects | Gentamicins/pharmacology | Catheter-Related Infections/prevention & control | Pseudomonas aeruginosa/drug effects | Staphylococcal Infections/prevention & control | Catheter-Related Infections/drug therapy | Central Venous Catheters/microbiology | Escherichia coli/drug effects | Bacteriology | Microbiology and Parasitology | Central Venous Catheters/adverse effects | Arginine/pharmacology | Pseudomonas Infections/prevention & control | Escherichia coli Infections/prevention & control | Pseudomonas Infections/drug therapy
Journal Article
Burns, ISSN 0305-4179, 2016, Volume 43, Issue 3, pp. 642 - 653
Critical Care | Nosocomial infection | Burn wound infection | Pneumonia | Urinary tract infection | Health care related infection | Burns | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Dermatology | Surgery | Science & Technology | Escherichia coli | Humans | Middle Aged | Child, Preschool | Male | Young Adult | Folliculitis - epidemiology | Aged, 80 and over | Urinary Tract Infections - microbiology | Catheter-Related Infections - epidemiology | Child | Infant, Newborn | Staphylococcus aureus | Escherichia coli Infections - drug therapy | Bacteremia - drug therapy | Pseudomonas Infections - microbiology | Wound Infection - epidemiology | Catheter-Related Infections - drug therapy | Drug Resistance, Microbial | Escherichia coli Infections - epidemiology | Acinetobacter baumannii | Catheter-Related Infections - microbiology | Adolescent | Bacteremia - epidemiology | Infant | Bacteremia - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Adult | Female | Pseudomonas aeruginosa | Staphylococcal Infections - microbiology | Wound Infection - drug therapy | Acinetobacter Infections - microbiology | Staphylococcal Infections - drug therapy | Colombia - epidemiology | Klebsiella Infections - drug therapy | Central Venous Catheters | Pneumonia - epidemiology | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Folliculitis - microbiology | Pneumonia - microbiology | Klebsiella Infections - microbiology | Oxacillin - therapeutic use | Burns - epidemiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Pneumonia - drug therapy | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Acinetobacter Infections - epidemiology | Wound Infection - microbiology | Aged | Folliculitis - drug therapy | Klebsiella pneumoniae | Development and progression | Burns and scalds | Surgery, Plastic | Health aspects | Staphylococcus aureus infections | Analysis | Bacterial pneumonia | Mortality | Urinary tract infections | Bacteria | Disease susceptibility | Antibacterial agents | Index Medicus
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 10/2019, Volume 200, Issue 7, pp. E45 - E67
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Community-Acquired Infections - diagnosis | Culture Techniques | United States | Humans | Pneumonia, Pneumococcal - diagnosis | Haemophilus Infections - diagnosis | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Adult | Haemophilus Infections - metabolism | Drug Therapy, Combination | Haemophilus Infections - drug therapy | Pneumonia, Mycoplasma - metabolism | Severity of Illness Index | Chlamydophila Infections - drug therapy | Blood Culture | Chlamydophila Infections - metabolism | Legionellosis - diagnosis | Hospitalization | Legionellosis - drug therapy | Pneumonia, Bacterial - diagnosis | Ambulatory Care | Moraxellaceae Infections - drug therapy | Chlamydophila Infections - diagnosis | Pneumonia, Pneumococcal - metabolism | Antigens, Bacterial - urine | Pneumonia, Staphylococcal - drug therapy | Moraxellaceae Infections - metabolism | Pneumonia, Staphylococcal - diagnosis | Pneumonia, Staphylococcal - metabolism | Sputum | Pneumonia, Bacterial - drug therapy | Legionellosis - metabolism | Pneumonia, Pneumococcal - drug therapy | Radiography, Thoracic | Moraxellaceae Infections - diagnosis | Macrolides - therapeutic use | beta-Lactams - therapeutic use | Pneumonia, Mycoplasma - diagnosis | Pneumonia, Mycoplasma - drug therapy | Clinical trials | Pneumonia | Adults | Medical diagnosis | Medical treatment | Index Medicus | Abridged Index Medicus | community-acquired pneumonia | American Thoracic Society Documents | pneumonia; patient management
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 03/2016, Volume 193, Issue 5, pp. 504 - 515
Healthy controls | Cystic fibrosis | Microbiota | Nasopharynx | Longitudinal | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Carrier State - epidemiology | Streptococcus mitis - genetics | Prospective Studies | Humans | Corynebacterium Infections - epidemiology | Carrier State - microbiology | Haemophilus Infections - epidemiology | Infant | Male | Corynebacterium Infections - microbiology | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Enterobacteriaceae Infections - epidemiology | Female | Staphylococcal Infections - microbiology | Nasopharynx - microbiology | Real-Time Polymerase Chain Reaction | Burkholderia Infections - microbiology | Haemophilus Infections - drug therapy | Infant, Newborn | Staphylococcus aureus - genetics | Moraxellaceae Infections - epidemiology | Streptococcal Infections - microbiology | Burkholderia - genetics | Staphylococcal Infections - drug therapy | Burkholderia Infections - epidemiology | Cystic Fibrosis - microbiology | Enterobacteriaceae Infections - microbiology | Enterobacteriaceae - genetics | Moraxellaceae Infections - microbiology | Streptococcal Infections - epidemiology | Haemophilus influenzae - genetics | Corynebacterium - genetics | Cystic Fibrosis - epidemiology | Moraxellaceae Infections - drug therapy | DNA, Bacterial - genetics | Staphylococcal Infections - epidemiology | Corynebacterium Infections - drug therapy | Microbiota - genetics | Burkholderia Infections - drug therapy | Haemophilus Infections - microbiology | RNA, Ribosomal, 16S - genetics | Streptococcal Infections - drug therapy | Moraxella - genetics | Cohort Studies | Enterobacteriaceae Infections - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
European journal of clinical microbiology & infectious diseases, ISSN 0934-9723, 9/2018, Volume 37, Issue 9, pp. 1627 - 1636
Medical Microbiology | Biomedicine | Targeted therapy | Escherichia coli | Bloodstream infections | Internal Medicine | ESKAPE | Antimicrobial resistance | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Escherichia coli - drug effects | Humans | Escherichia coli Infections - blood | Molecular Targeted Therapy | Incidence | Bacteremia - microbiology | Hospitals, Teaching - statistics & numerical data | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Drug Resistance, Multiple, Bacterial | Staphylococcal Infections - microbiology | Catheter-Related Infections - epidemiology | Cross Infection - epidemiology | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Klebsiella Infections - drug therapy | Pseudomonas Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Bacteremia - drug therapy | Escherichia coli Infections - microbiology | beta-Lactamases - drug effects | Klebsiella Infections - microbiology | Pseudomonas Infections - microbiology | Cross Infection - drug therapy | Catheter-Related Infections - drug therapy | Bacterial Proteins - drug effects | Escherichia coli Infections - epidemiology | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Escherichia coli - genetics | Escherichia coli - isolation & purification | Catheter-Related Infections - microbiology | Cross Infection - microbiology | Bacteremia - epidemiology | Anti-Bacterial Agents - pharmacology | Drug resistance in microorganisms | Pneumonia | Bacterial pneumonia | Beta lactamases | Health aspects | Public health | Klebsiella | Health care | Pathogens | Communities | Carbapenemase | Antimicrobial agents | Infections | Drug resistance | Antiinfectives and antibacterials | Methicillin | E coli | Pseudomonas aeruginosa | Bacteria | Meropenem | Trends | Ciprofloxacin | Active control | Emergency medical services | Ceftazidime | Index Medicus
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 2001, Volume 163, Issue 6, pp. 1371 - 1375
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Medical sciences | Antibacterial agents | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recurrence | Enterobacteriaceae Infections - diagnosis | Prospective Studies | Humans | Middle Aged | Haemophilus Infections - blood | Male | Pneumococcal Infections - diagnosis | Haemophilus Infections - diagnosis | Pseudomonas Infections - blood | Respiration, Artificial - adverse effects | Time Factors | Pneumonia - diagnosis | Pneumonia - blood | Pneumococcal Infections - etiology | Risk Factors | Enterobacteriaceae Infections - etiology | Pseudomonas Infections - diagnosis | Cross Infection - drug therapy | Pneumococcal Infections - blood | Cross Infection - diagnosis | Bacterial Infections - blood | Cross Infection - blood | Enterobacteriaceae Infections - drug therapy | Practice Guidelines as Topic | Staphylococcal Infections - etiology | Pneumococcal Infections - drug therapy | Pseudomonas Infections - etiology | Cross Infection - etiology | Bacterial Infections - etiology | Infection Control - methods | Haemophilus influenzae | Bronchoalveolar Lavage Fluid - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Adult | Female | Leukocyte Count | Haemophilus Infections - drug therapy | Staphylococcal Infections - blood | Staphylococcal Infections - drug therapy | Pneumonia - etiology | Pseudomonas Infections - drug therapy | Proportional Hazards Models | Treatment Outcome | Haemophilus Infections - etiology | Staphylococcal Infections - diagnosis | Pneumonia - drug therapy | Enterobacteriaceae Infections - blood | Aged | Bacterial Infections - diagnosis | Drug Monitoring | Index Medicus | Abridged Index Medicus
Journal Article
Clinical orthopaedics and related research, ISSN 0009-921X, 7/2013, Volume 471, Issue 7, pp. 2383 - 2399
Surgical Orthopedics | Medicine & Public Health | Sports Medicine | Orthopedics | Surgery | Conservative Orthopedics | Medicine/Public Health, general | Life Sciences & Biomedicine | Science & Technology | Community-Acquired Infections - diagnosis | Community-Acquired Infections - therapy | Community-Acquired Infections - transmission | Hospital Costs | Cross Infection - economics | Humans | Orthopedic Procedures - adverse effects | Infection Control - methods | Cost Savings | Cross Infection - transmission | Staphylococcal Infections - microbiology | Surgical Wound Infection - transmission | Cross Infection - prevention & control | Mass Screening - economics | Community-Acquired Infections - economics | Surgical Wound Infection - economics | Anti-Infective Agents - therapeutic use | Treatment Outcome | Staphylococcal Infections - therapy | Staphylococcal Infections - transmission | Surgical Wound Infection - prevention & control | Staphylococcal Infections - diagnosis | Staphylococcal Infections - economics | Cost-Benefit Analysis | Cross Infection - microbiology | Surgical Wound Infection - diagnosis | Cross Infection - diagnosis | Orthopedic Procedures - economics | Staphylococcal Infections - prevention & control | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Program Evaluation | Surgical Wound Infection - microbiology | Community-Acquired Infections - microbiology | Infection Control - economics | Online health care information services | Orthopedic surgery | Health aspects | Analysis | Staphylococcal infections | Staphylococcus aureus | Index Medicus | Abridged Index Medicus | Survey
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 9/2015, Volume 61, Issue suppl 2, pp. S69 - S78
telavancin | necrotizing infections | skin infections | cellulitis | soft-tissue infections | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Skin Diseases, Bacterial - microbiology | Humans | Skin Diseases, Bacterial - drug therapy | Oxazolidinones - therapeutic use | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Skin Diseases, Bacterial - epidemiology | Gram-Positive Bacterial Infections - microbiology | Soft Tissue Infections - drug therapy | Staphylococcal Infections - microbiology | Daptomycin - therapeutic use | Staphylococcal Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Gram-Negative Bacterial Infections - drug therapy | Clinical Trials as Topic | Soft Tissue Infections - epidemiology | Gram-Positive Bacterial Infections - epidemiology | Daptomycin - pharmacology | Soft Tissue Infections - microbiology | Staphylococcal Infections - epidemiology | Oxazolidinones - pharmacology | Gram-Negative Bacterial Infections - epidemiology | Anti-Bacterial Agents - pharmacology | North America - epidemiology | Aminoglycosides - pharmacology | Gram-Positive Bacterial Infections - drug therapy | Aminoglycosides - therapeutic use | Staphylococcus infections | Antimicrobial agents | Mortality | Medical treatment | Morbidity | Streptococcus infections | Index Medicus
Journal Article